GLP1R and type 2 diabetes mellitus: To put things into perspective, SGLT2is, which were first approved for the therapy of T2DM eight years later than GLP1-RAs, have been tested in a much more extensive manner in cardiotoxicity, and high-quality data have been provided by randomized controlled trials [70] and meta-analyses [71], especially with regard to anthracycline-mediated cardiotoxicity.